Human papillomavirus 16E6 suppresses major histocompatibility complex class I by upregulating lymphotoxin expression in human cervical cancer cells

Biochemical and Biophysical Research Communications

Volumn 409, Issue 4, 2011, Pages 792-798

  Kim, Dong Hern ^a   Kim, Eun Mi ^a,d   Lee, Eun Hee ^a   Ji, Kon Young ^a   Yi, Jawoon ^a   Park, Min ^a   Kim, Kwang Dong ^b   Cho, Yong Yeon ^c   Kang, Hyung Sik ^a  

^a Chonnam National University   (South Korea)

^b Gyeongsang National University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Cervical cancer; HPV16E6; Lymphotoxin; Major histocompatibility complex; Tumor surveillance

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN; LYMPHOTOXIN BETA RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; PROTEIN E6; PROTEIN E7; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL ASSAY; CELL SURFACE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DNA BINDING; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLEEN CELL; TRANSGENIC MOUSE; UTERINE CERVIX CANCER; VIRUS GENE; WILD TYPE;

ANIMALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN-ALPHA; LYMPHOTOXIN-BETA; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

EID: 79959236072     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.090     Document Type: Article

References (22)

1. Munger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M., Zacny V.L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001, 20:7888-7898.
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.
3. Thomas M., Pim D., Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999, 18:7690-7700.
4. Watson R.A., Thomas M., Banks L., Roberts S. Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J. Cell Sci. 2003, 116:4925-4934.
5. Dierssen J.W., de Miranda N.F., Ferrone S., van Puijenbroek M., Cornelisse C.J., Fleuren G.J., van Wezel T., Morreau H. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer 2007, 7:33.
6. Paul N.L., Ruddle N.H. Lymphotoxin. Annu. Rev. Immunol. 1988, 6:407-438.
7. Spies T., Morton C.C., Nedospasov S.A., Fiers W., Pious D., Strominger J.L. Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc. Natl. Acad. Sci. USA 1986, 83:8699-8702.
8. Bottley G., Watherston O.G., Hiew Y.L., Norrild B., Cook G.P., Blair G.E. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 2008, 27:1794-1799.
9. Smahel M., Sima P., Ludvikova V., Marinov I., Pokorna D., Vonka V. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 2003, 21:1125-1136.
10. Park Y.W., Kee S.J., Cho Y.N., Lee E.H., Lee H.Y., Kim E.M., Shin M.H., Park J.J., Kim T.J., Lee S.S., Yoo D.H., Kang H.S. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum. 2009, 60:1753-1763.
11. Garrido F., Algarra I., Garcia-Lora A.M. The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol. Immunother. 2010, 59:1601-1606.
12. Griep A.E., Herber R., Jeon S., Lohse J.K., Dubielzig R.R., Lambert P.F. Tumorigenicity by human papillomavirus type 16 E6 and E7 in transgenic mice correlates with alterations in epithelial cell growth and differentiation. J. Virol. 1993, 67:1373-1384.
13. Yutsudo M., Okamoto Y., Hakura A. Functional dissociation of transforming genes of human papillomavirus type 16. Virology 1988, 166:594-597.
14. Pober J.S., Lapierre L.A., Stolpen A.H., Brock T.A., Springer T.A., Fiers W., Bevilacqua M.P., Mendrick D.L., Gimbrone M.A. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J. Immunol. 1987, 138:3319-3324.
15. Andrews J.S., Berger A.E., Ware C.F. Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma. J. Immunol. 1990, 144:2582-2591.
16. Harcourt B.H., Sanchez A., Offermann M.K. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J. Virol. 1999, 73:3491-3496.
17. Chang C.C., Campoli M., Ferrone S. HLA class I defects in malignant lesions: what have we learned?. Keio J. Med. 2003, 52:220-229.
18. Crook T., Vousden K.H. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J. 1992, 11:3935-3940.
19. Eugster H.P., Muller M., Karrer U., Car B.D., Schnyder B., Eng V.M., Woerly G., Le Hir M., di Padova F., Aguet M., Zinkernagel R., Bluethmann H., Ryffel B. Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-alpha double-deficient mice. Int. Immunol. 1996, 8:23-36.
20. Taniguchi S.I., Shong M., Giuliani C., Napolitano G., Saji M., Montani V., Suzuki K., Singer D.S., Kohn L.D. Iodide suppression of major histocompatibility class I gene expression in thyroid cells involves enhancer A and the transcription factor NF-kappa B. Mol. Endocrinol. 1998, 12:19-33.
21. Pober J.S., Orosz C.G., Rose M.L., Savage C.O. Can graft endothelial cells initiate a host anti-graft immune response?. Transplantation 1996, 61:343-349.
22. Ting J.P., Baldwin A.S. Regulation of MHC gene expression. Curr. Opin. Immunol. 1993, 5:8-16.